Key result
SGLT2 inhibitors and myosin inhibitors may correct diverse cellular pathomechanisms in early and advanced hypertrophic cardiomyopathy.
SGLT2 inhibitors and myosin inhibitors represent potential therapeutic strategies to address the underlying cellular pathomechanisms of hypertrophic cardiomyopathy.
Early cardiomyocyte changes in hypertrophic cardiomyopathy (HCM) include impaired myofilament relaxation and high myofilament ATP utilization which have been linked with changes in metabolism and ion handling. During progression of disease, hypertrophic remodelling and reduced beta-adrenergic receptor signalling aggravate diastolic dysfunction. SGLT2i and myosin inhibitors may correct the diverse cellular HCM pathomechanisms at early and advanced disease stage.
No takes yet. Share an insight, caveat, or question.
Jolanda van der Velden (2025) conducted a review in Hypertrophic cardiomyopathy (HCM). SGLT2 inhibitors and myosin inhibitors was evaluated. SGLT2 inhibitors and myosin inhibitors may correct diverse cellular pathomechanisms in early and advanced hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: